Justin Chakma - Dec 10, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Dec 10, 2024
Transactions value $
-$615,625
Form type
4
Date filed
12/12/2024, 05:41 PM
Previous filing
Dec 6, 2024
Next filing
Dec 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $42K +50K +36.66% $0.84 186K Dec 10, 2024 Direct
transaction SPRY Common Stock Sale -$658K -50K -26.83% $13.15 136K Dec 10, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -50K -100% $0.00 0 Dec 10, 2024 Common Stock 50K $0.84 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 Immediately exercisable.